Clinical Trial

Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Study acronym: SIERRA
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia (AML).
Protocol Amendment History 25 amendments
This ClinicalTrials.gov record has been amended 25 times since 2016-01-26; most recent amendment 2023-07-18.
Status change: Recruiting → Active, Not Recruiting 2022-02-14
Status change: Not Yet Recruiting → Recruiting 2016-11-28
Trial Details
NCT Number NCT02665065
Lead Sponsor Actinium Pharmaceuticals
Conditions Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML +1 more
Enrollment 153 participants
Start Date 2016-06
Primary Completion 2022-06 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2023-07-19